Explore the website

Technical Briefing Papers

Deep dives into and analysis of issues that impact access to medicines.

Our Work on Covid-19

Our views on what governments and the international community can do to fight this pandemic and prepare for the next one.

Our Blog

Timely and topical analysis on the day-to-day issues in intellectual property and health.

The TRIPS Flexibilities Database

Instances when authorities have invoked, planned to/were asked to invoke a flexibility contained in the TRIPS Agreement for public health reasons.

Tools for Access to Medicines

Tools to help governments and others looking to increase access to medicines by using flexibilities in intellectual property law.

Meet the Team

Learn about Medicines Law & Policy's team of legal and policy experts.

Subscribe to our newsletter and never miss a post!

* indicates required

Medicines Law & Policy will use the information you provide to keep you up-to-date when we post new research and insight. You can change your mind about receiving our newsletter any time by clicking the unsubscribe link in the footer of any email you receive from us. We will treat your information with respect. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

Explore the website

Technical Briefing Papers

Deep dives into and analysis of issues that impact access to medicines.

Our Work on Covid-19

Our views on what governments and the international community can do to fight this pandemic and prepare for the next one.

Our Blog

Timely and topical analysis on the day-to-day issues in intellectual property and health.

The TRIPS Flexibilities Database

Instances when authorities have invoked, planned to/were asked to invoke a flexibility contained in the TRIPS Agreement for public health reasons.

Tools for Access to Medicines

Tools to help governments and others looking to increase access to medicines by using flexibilities in intellectual property law.

Meet the Team

Learn about Medicines Law & Policy's team of legal and policy experts.

We value your privacy

We use cookies to enhance your browsing experience, serve personalised content, and analyse our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Menu
Contact Us
Subscribe
Menu

Medicines Law & Policy releases analysis, tools, and data to influence policy and practices to improve access to medicines.

Pandemic Accord

ML&P has been closely following the process towards the creation of a new international instrument to better prevent, prepare...

Our research

ML&P delves into complex public health issues, seeking to make the legal implications of international legislation clearer, and to...

Blog

Medicines Law & Policy periodically will post timely analysis and insight into current events related to intellectual property and...

TRIPS Flexibilities Database

The TRIPS Flexibilities Database contains instances when authorities have invoked, planned to invoke, or have been asked to invoke...

Latest Blog Posts from Medicines Law & Policy

FDA approval of injectable lenacapavir for Pre-Exposure Prophylaxis (PrEP) opens the road to ending HIV

Ellen 't Hoen -
On 18th June 2025, the US Food and Drug Administration (FDA) approved the use of long-acting antiretroviral medicine lenacapavir (LEN-LA), for the prevention of...

Transfer of technology and know-how for the production of pandemic-related health products in the WHO Pandemic Agreement: The proverbial half glass 

Ellen 't Hoen -
A version of this brief was published on 13 June '25 by the Graduate Institute as part of their 'Governing Pandemic Snapshot' series: https://www.governingpandemics.org/gp-snapshot During...

World Health Assembly adopts the Pandemic Agreement

Kaitlin Mara -
"I see no objection, the resolution is adopted," said Teodoro J. Herbosa, Secretary of Health of the Philippines and President of the 78th World...

The People vs. AbbVie

Ellen 't Hoen -
Today, 9 May 2025, is an important day in court for the Dutch Pharmaceutical Accountability Foundation (PAF). In February 2023, PAF started a court...

The Pandemic Agreement is here

Ellen 't Hoen -
In December 2021, the member states of the World Health Organization decided “to draft and negotiate a WHO convention, agreement or other international instrument...

Pharmaceutical patents and data exclusivity in an age of AI-driven drug discovery and development

Christopher Garrison -
This is an excerpt from a longer report on AI, medicines development and the patent system. Download the full report here (or by clicking...

Expanding local production is essential for pandemic preparedness. It requires, however, transfer of technology.

Ellen 't Hoen -
Madam co-chairs, delegates,  This very week, from 7 to 9 April the 3rd World Local Production Forum is taking place in Abu Dhabi. Actions towards...

Respect for intellectual property law includes respecting the flexibilities it contains to protect the public interest: ML&P’s opening statement to the INB

Kaitlin Mara -
Thank you for the opportunity to speak. And for the latest draft of the pandemic agreementshared with us on 26 March. In particular, we...

Will Europe block the Pandemic Agreement because of one word?

Guilherme Ferrari Faviero and Ellen 't Hoen -
This commentary originally appeared in the Brussels Times, and is available here. The Pandemic Agreement negotiations began in December of 2021. Sufficiently motivated by the...

“Mutually agreed terms and conditions,” says it all.

Ellen 't Hoen -
On 4 March, Politico reported that the Polish presidency of the Council of the European Union (EU) is expressing doubt that the Pandemic Agreement...
See all blogs

Bluesky

Follow the ML&P team on Bluesky:

Medicines Law & Policy
Ellen 't Hoen
Kaitlin Mara
Katrina Perehudoff

Research Highlights

Current drafts of the WHO Pandemic Accord lack a provision for access to knowhow/trade secrets. We drafted one.

Medicines Law & Policy

15 July 2022

Seven recommendations for sharing IP, know-how and technology – report of Global Expert Group on the Pandemic Treaty

BMJ Global Health

15 July 2022

Scaling-up Vaccine Production Capacity: Legal Challenges and Recommendations

The Independent Panel for Pandemic Preparedness and Response

May 2021

What is the ‘know-how gap’ problem and how might it impact scaling up production of Covid-19 related diagnostics, therapies and vaccines?

Medicines Law & Policy

May 2021

EU Review of Pharmaceutical Incentives: Recommendations for Change

Medicines Law & Policy

May 2021

Posts by Topic

Medicines Law & Policy

Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.

Never miss a post! Sign up for ML&P's newsletter.

This work is licensed under Creative Commons. You are free to share, with attribution and without changes, for non-commercial purposes.